Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

InxMed Licenses Rights to Escugen’s Linker-Payload Platform for ADC Candidates

publication date: Dec 20, 2023

Nanjing InxMed licensed rights to use an EZWi-Fit® linker-payload platform developed by Shanghai’s Escugen to develop ADCs containing next-gen tumor-associated antigens (TAAs). InxMed, a company that develops innovative therapies to counteract drug resistance, will apply Escugen’s platform to several novel ADC candidates. The company believes its next-gen ADCs will have better tumor selectivity and greater potency, allowing the possibility of combinations with other candidates. InxMed will have the right for development, manufacturing and commercialization of the ADC candidates. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here